Abstract:Abstract Introduction: Epigallocatechin gallate (EGCG) is a polyphenol present in green tea that is known for its anti-oxidant, anti-inflammatory, anti-angiogenic, pro-apoptotic, and anti-cancer properties. However, EGCG has not been systematically evaluated on a large panel of cancer cell lines. We hypothesized that EGCG exhibits varying effects on specific cancer cell genetic backgrounds and types. This study aimed to provide a comprehensive analysis of EGCG on both cell viability and gene expression profiles. Methods: 750 cancer cell lines were cultured and seeded in 1536-well plates for cell viability studies (by the CTD2 Center at the Broad Institute). After 24 h, cells were treated with 16 two-fold serial dilutions of EGCG. After 72 h, cell viability was assayed using CellTiter-Glo. For gene expression profiling (with the Broad Institute and NIH), 8 cell lines were treated with 10 μM EGCG for 6 and 24 h, and transcriptomes were assessed using Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays. The CMap large-scale transcriptome dataset was used for comparisons. Results: EGCG had the highest potency in the non-Hodgkins B-cell lymphoma cell line DoHH2 (IC50=0.42 μM), the myeloid leukemia cell line Ku812 (IC50=3.76 μM), and the multiple myeloma cell line KMS-28BM (IC50=4.57 μM). Tissue-of-origin analysis showed that EGCG was most potent against lymphoid cancers, and least potent against prostate cancers. Bioinformatics-based analyses found that EGCG-treated cells resembled cells overexpressing CHEK2, DDP4, CBLC, ZNF350, and TRAF6, and cells underexpressing TRIM16. EGCG-induced gene expression resembled lapatinib and sulfasalazine treatment. Conclusions: This study provides a comprehensive examination of the differential impact of EGCG treatment on cancer cells. Subsequent research on the timing and duration of the changes, along with pathway enrichment analyses, will potentially guide the translational potential of EGCG and its chemical analogs in personalized cancer treatment approaches. Citation Format: Aria Panchal, Jacqueline H. Law, Clement Lo, Kenneth W. Yip. Anticancer mechanisms of epigallocatechin gallate revealed via cellular and molecular profiling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 521.

Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications

Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer

EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways

Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer

The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer

(-)-Epigallocatechin-3-gallate Induces Non-Apoptotic Cell Death in Human Cancer Cells Via Ros-Mediated Lysosomal Membrane Permeabilization

Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement

Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG

Abstract 521: Anticancer mechanisms of epigallocatechin gallate revealed via cellular and molecular profiling

Effects of (−)-Epigallocatechin Gallate on Some Protein Factors Involved in the Epidermal Growth Factor Receptor Signaling Pathway

Epigallocatechin Gallate-Β-lactoglobulin Nanoparticles Improve the Antitumor Activity of EGCG for Inducing Cancer Cell Apoptosis

Green Tea Catechin, Epigallocatechin-3-Gallate, Inhibits Vascular Endothelial Growth Factor Angiogenic Signaling By Disrupting The Formation Of A Receptor Complex

EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment

Epigallocatechin Gallate Inhibits the Growth of Human Lung Cancer by Directly Targeting the EGFR Signaling Pathway.

Research Progress in Anticancer Mechanism of Epigallocatechin Gallate(egcg)

Molecular Targets for Cancer Chemoprevention by (-)-Epigallocatechin Gallate of Green Tea

Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer